Alberta DermaSurgery Centre | Edmonton, AB
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Note: Other protocol-defined Inclusion criteria apply.
Exclusion criteria
Note: Other protocol-defined Exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Peter Lichtlen, MD, PhD, BBA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal